Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination.
In seeking to define the relative value of transrectal ultrasound (TRUS), prostate specific antigen (PSA) and digital rectal examination (DRE) in the diagnosis of prostatic cancer, 863 patients were studied and the findings compared. DRE detected malignancy in 0.3% of the population of asymptomatic "normal" men undergoing routine health screening, and in 1.6% of patients who consulted their General Practitioner for one reason or another. In patients who attended our out-patient department with a variety of urological symptoms (not necessarily prostatic), TRUS suggested malignancy in 2% of those glands which were pronounced normal on DRE. Significantly elevated PSA detected malignancy in 0.3% of the patients undergoing routine health screening. (Although this figure equals the pick-up rate by DRE in this group, they were not necessarily the same patients). When these 3 investigations are summated, the pick-up rate is twice as high as when a single parameter is used.
Perrin
P
P
Department of Urology, Hôpital de l'Antiquaille, Lyon, France.
Maquet
J H
JH
Bringeon
G
G
Devonec
M
M
D000951:Antigens, Neoplasm / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010808:Physical Examination; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011467:Prostate / Q000000981:diagnostic imaging; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology / Q000517:prevention & control*; D012007:Rectum / Q000473:pathology*; D014463:Ultrasonography
D000951:Antigens, Neoplasm; D017430:Prostate-Specific Antigen